niraparib tosylate monohydrate and abiraterone acetate

FDA Drug Profile

niraparib tosylate monohydrate and abiraterone acetate is listed in the FDA National Drug Code directory with 2 NDC codes. Available dosage form: tablet, film coated.

Drug details

Generic Name
niraparib tosylate monohydrate and abiraterone acetate
Sponsor
Patheon France S.A.S.
NDC Codes
2
Dosage Forms
TABLET, FILM COATED
Active Ingredients
ABIRATERONE ACETATE, NIRAPARIB TOSYLATE MONOHYDRATE

Indications and Usage

1 INDICATIONS AND USAGE AKEEGA with prednisone is indicated for the treatment of adult patients with deleterious or suspected deleterious BRCA2 -mutated ( BRCA2 m) metastatic castration-sensitive prostate cancer (mCSPC). AKEEGA with prednisone is indicated for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for AKEEGA [see Dosage and Administration (2.1) ] . AKEEGA is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with: deleterious or suspected deleterious BRCA2 -mutated ( BRCA2 m) metastatic castration-sensitive prostate cancer (mCSPC). deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for AKEEGA. ( 1 , 2.1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.